Picture

Northwestern Medicine
​Breakthroughs for Physicians

​​
  • Home
  • Specialties
    • Cardiovascular >
      • Research
      • Clinical Breakthroughs
      • News
    • Endocrinology >
      • Clinical Breakthroughs In Endocrinology
      • Research In Endocrinology
      • News
    • ENT (Otolaryngology) >
      • Clinical Breakthroughs
      • Research
      • News
    • Gastroenterology >
      • Clinical Breakthroughs
      • Research
      • News
    • Geriatrics >
      • Clinical Breakthroughs
      • Research
      • News
    • Neurosciences >
      • Rare and Complex Brain Tumors
      • Research
      • COVID-19 and Neurosciences
      • News
      • Clinical Breakthroughs
    • OB-GYN >
      • Clinical Breakthroughs
      • Research
      • News
    • Oncology >
      • Clinical Breakthroughs
      • Research
      • News
    • Ophthalmology >
      • Clinical Breakthroughs
      • Research
      • News
    • Organ Transplant >
      • Clinical Breakthroughs
      • Research
      • News
    • Orthopaedics >
      • Clinical Breakthroughs
      • Research
      • News
    • Psychiatry >
      • Clinical Breakthroughs
      • Research
      • News
    • Pulmonary >
      • Clinical Breakthroughs
      • Research
      • News
    • Rehabilitation >
      • Clinical Breakthroughs
      • News
    • Rheumatology >
      • Clinical Breakthroughs
      • Research
      • News
    • Urology >
      • Clinical Breakthroughs
      • Research
      • News
  • CME
  • REFERRALS
    • Refer to NM Cardiovascular
    • Refer to NM Neurosciences
    • Refer to Other Specialties

< BACK TO ONCOLOGY

Picture

lURIE CANCER CENTER AND Northwestern Medicine
​EXPERTS TO PRESENT AT ASCO 2022

Physicians and scientists from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine will present and discuss leading-edge research in cancer care at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7 at McCormick Place in Chicago and Online.

The theme of this year’s meeting, “Advancing Equitable Cancer Care Through Innovation,” reflects our shared commitment to knowledge-sharing across the global oncology community, and to ensuring that all patients have access to and benefit from the latest advances and high-quality cancer care.

Session
Presenter
*Discussant
Date & Time
Learn More

Genitourinary Cancer—Kidney and Bladder
The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214.


Abstract: 4502
David Cella, PhD, FASCO
June 3, 2022
2:45pm CDT
Arie Crown Theater
VIEW DETAILS

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
A phase Ib/II study of sotorasib combined with chemotherapy for second-line treatment of KRAS p. G12C–mutated advanced pancreatic cancer.

Abstract: TPS4194
​Poster: 162a
Devalingam Mahalingam, MBBChBAO
June 4, 2022
8:00am CDT
​In-Person & Live Stream | Hall A
VIEW DETAILS

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sequential pembrolizumab (pembro) and chemotherapy (chemo) in newly diagnosed, early unfavorable, or advanced-stage classical Hodgkin lymphoma (cHL): The phase 2 KEYNOTE-C11 study.

Abstract: TPS7584
Poster: 233b
Jane N Winter, MD
June 4, 2022
8:00am CDT

VIEW DETAILS

Special Sessions: Highlights of the Day Session II
​Highlights of the Melanoma / Skin Cancers Track

Credits: 1.25
Sunandana Chandra, MD*
June 4, 2022
8:48 - 9:00am CDT
​In-Person & Live Stream | Hall D1
VIEW DETAILS

Sarcoma
Sarcoma Subtypes or Emerging Biomarkers: Are We Making Progress in Precision Immunotherapy?

​
Credits: 3
Seth Pollack, MD
June 4, 2022
1:51pm CDT
In-Person & Live Stream | S406
view details

Window of Opportunity Clinical Trials in Neuro-oncology 
​Interrogating the Glioblastoma Tumor Immune Microenvironment Via Window-of-Opportunity Clinical Trials.
Amy B. Heimberger, MD
​​
June 4, 2022
3:00 - 4:15pm CDT
view details

Development Therapeutics - Immunotherapy 
​Microsatellite-stable tumors with high tumor mutational burden in association with tumor response to immune checkpoint inhibitor therapy across solid tumors and correlation with specific oncogenic alterations

Abstract: 2634
Poster 289
Imran Nizamuddin, MD
​
June 5, 2022
8:00pm CDT
In-Person & Live Stream | Hall A
view details

Session: Melanoma / Skin Cancers
Session Co-Chair:
Sunandana Chandra, MD
June 5, 2022
9:45am - 12:45pm CDT
In-Person & Live Stream | S100a
view details

Session: Central Nervous System Tumors
Session Chair and Moderator:
​Rimas Lukas, MD
​
June 5, 2022
​11:30am CDT
In-Person & Live Stream | S102
view details

Central Nervous System Tumors
Repeated opening of the blood-brain barrier with the skull-implantable SonoCloud-9 (SC9) device: Phase 1 trial of nab-paclitaxel and SC9 in recurrent glioblastoma.

​Abstract: 2016
​Poster: 354

Credits: 1.5
Adam M. Sonabend, MD
June 5, 2022
11:30am CDT
In-Person & On Demand | S102
view details

Patient-Centered Outcomes
Early Integration of Palliative Medicine for Locally Advanced and Metastatic Genitourniary Malignancies

​
Credits 1.25
David Cella, PhD, FASCO
June 5, 2022
​5:05pm CDT
In-Person & On Demand | S100bc
view details

Breast Cancer—Metastatic
EPIK-B4: A phase 2, randomized study of metformin (MET) extended release (XR) +/- dapagliflozin (DAPA) to prevent hyperglycemia (HG) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC) treated with alpelisib (ALP) and fulvestrant (FUL).


Abstract: TPS1107
Poster: 484a
William John Gradishar, MD, FACP, FASCO
June 6, 2022
8:00am CDT
view details

Innovative Immune Approaches in Prostate Cancer: A Case-Based Review of CAR T, BiTEs, and Next-Generation Agents
Session Chair and Moderator:
​David VanderWeele, MD, PhD
June 6, 2022
8:00am CDT
In-Person & Live Stream | Hall B1
view details

Central Nervous System Tumors​
Session Chair: 
​Roger Stupp, MD
June 6, 2022
11:30am - 2:30pm CDT
In-Person & Live Stream | S406
view details

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
​Optimizing Multimodal Therapy for Locoregional Non–Small Cell Lung Cancer

Credits: 1.5
Jyoti D. Patel, MD, FASCO*
J​une 6, 2022
11:52am CDT
In-Person & Live Stream | Hall D1
view details

Melanoma/Skin Cancers
Progression and mortality post-immunotherapy discontinuation among patients with BRAFV600-mutant (BRAF+) metastatic melanoma.

Abstract: 9531
Poster: 12​4
Sunandana Chandra, MD
J​une 6, 2022
1:15pm CDT
view details

Health Services Research and Quality Improvement
Lisocabtagene maraleucel (liso-cel) as second-line (2L) treatment (tx) for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Patient-reported outcomes (PRO) from the phase 2 PILOT study.


Abstract: 6567
​Poster: 350
Leo I. Gordon, MD
J​une 6, 2022
1:15pm CDT
​
In-Person & Live Stream | Hall A
view details

Health Services Research and Quality Improvement
Association of modifiable factors with financial burden and health literacy among patients with cancer.

Abstract: 6573
​Poster: 356
Betina Yanez, PhD
J​une 6, 2022
1:15pm CDT
In-Person & Live Stream | Hall A
view details

Health Services Research and Quality Improvement
​Longitudinal changes in financial burden in patients with colorectal cancer treated with curative intent: Primary results of EAQ162CD.

Abstract: 5033
​Poster: 218
Sheetal M. Kircher, MD
J​une 6, 2022
1:15pm CDT
​
In-Person & Live Stream | Hall A
view details

Genitourinary Cancer—Prostate, Testicular, and Penile​
Epigenetic age acceleration in U.S. testicular cancer survivors.

Abstract: 5033
​Poster: 217
Yinan Zheng, PhD
J​une 6, 2022
1:15pm CDT
​​In-Person & Live Stream | Hall A
view details

Genitourinary Cancer—Prostate, Testicular, and Penile​
Candidate surrogate endpoints in advanced prostate cancer: Aggregate meta-analysis of 143 randomized trials.

Abstract: 5040
Poster: 224
Laila A. Gharzai, PhD
J​une 6, 2022
1:15pm CDT
​
In-Person & Live Stream | Hall A
view details

Genitourinary Cancer—Prostate, Testicular, and Penile​
BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.


Abstract: 5018
​Poster: 202

​Credits: 1.5
Maha H.A. Hussain, MD, FASCO, FACP
J​une 6, 2022
5:25pm CDT
​
In-Person & Live Stream | Arie Crown Theater
​
view details

​NORTHWESTERN MEDICINE onCOLOGY

The Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital is a global leader in a broad range of cancer types thanks to its dedication to comprehensive research, world-renowned faculty and staff and its commitment to making ongoing advances in medical, surgical, radiation and interventional oncology. The Lurie Cancer Center is designated by the National Cancer Institute as one of only 51 comprehensive cancer in the nation recognized  for their scientific leadership, resources and the depth and breadth of their research. In addition, Lurie Cancer Center is a founding member of the National Comprehensive Cancer Network (NCCN) and our physicians actively participate in writing NCCN patient guidelines for each type cancer.
BREAKTHROUGHS
RESEARCH
COVID-19

Find a Lurie Cancer Center Physician Expert

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients.

Find an Oncologist

follow northwestern medicine oncology

NM Oncology on Twitter
NM Oncology Video Channel
NM Better Edge Podcast

Northwestern Medicine Breakthroughs for Physicians

About Us     Terms of Use     Privacy Policy     How to Vote for U.S. News & World Report Best Hospitals
© 2025 Northwestern Medicine® and Northwestern Memorial HealthCare. 
Northwestern Medicine® is a trademark of Northwestern Memorial HealthCare, used by Northwestern University
Connect with us
[email protected]
International physicians, contact [email protected]
  • Home
  • Specialties
    • Cardiovascular >
      • Research
      • Clinical Breakthroughs
      • News
    • Endocrinology >
      • Clinical Breakthroughs In Endocrinology
      • Research In Endocrinology
      • News
    • ENT (Otolaryngology) >
      • Clinical Breakthroughs
      • Research
      • News
    • Gastroenterology >
      • Clinical Breakthroughs
      • Research
      • News
    • Geriatrics >
      • Clinical Breakthroughs
      • Research
      • News
    • Neurosciences >
      • Rare and Complex Brain Tumors
      • Research
      • COVID-19 and Neurosciences
      • News
      • Clinical Breakthroughs
    • OB-GYN >
      • Clinical Breakthroughs
      • Research
      • News
    • Oncology >
      • Clinical Breakthroughs
      • Research
      • News
    • Ophthalmology >
      • Clinical Breakthroughs
      • Research
      • News
    • Organ Transplant >
      • Clinical Breakthroughs
      • Research
      • News
    • Orthopaedics >
      • Clinical Breakthroughs
      • Research
      • News
    • Psychiatry >
      • Clinical Breakthroughs
      • Research
      • News
    • Pulmonary >
      • Clinical Breakthroughs
      • Research
      • News
    • Rehabilitation >
      • Clinical Breakthroughs
      • News
    • Rheumatology >
      • Clinical Breakthroughs
      • Research
      • News
    • Urology >
      • Clinical Breakthroughs
      • Research
      • News
  • CME
  • REFERRALS
    • Refer to NM Cardiovascular
    • Refer to NM Neurosciences
    • Refer to Other Specialties